Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 5, 2010, Pages 563-565

  Taiwo, Babafemi O ^a   Idoko, John A ^b   Marcelin, Anne Geneviève ^c   Otoh, Ihedinachi ^b   Reddy, Susheel ^a   Iyaji, Paul G ^b   Agbaji, Oche ^b   Penugonda, Sudhir ^a   Agaba, Patricia A ^b   Murphy, Robert L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF JOS   (Nigeria)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS LOAD;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION, MISSENSE; NIGERIA;

EID: 77954978526     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e5112f     Document Type: Letter

References (8)

1. Taiwo BO, Idoko JA, Welty L, et al. Assessing the virologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2010;54:85-92.
2. Kumarasamy N, Madhavan V, Venkatesh KK, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009;49:306-309.
3. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleo-side reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127-1134.
4. Koyalta D, Charpentier C, Beassamda J, et al. High frequency of antiretroviral drug resistance among HIV-1 infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis. 2009;49:155-159.
5. Hanson DL, Adje-Toure C, Talla-Nzussouo N, et al. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Cote d'Ivoire. AIDS Res Hum Retro-viruses. 2009;25:489-495.
6. Gardner EM, Burman WJ, Steiner JF, et al. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23:1035-1046.
7. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53:696-699.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2008. To p H I V M e d. 2009;16:138-145.